RET and non-small cell lung carcinoma: The Phase I/II LIBRETTO-001 trial evaluating selpercatinib in a cohort of previously treated NSCLC patients with RET rearrangements (N = 105) also demonstrated marked antitumor efficacy with an ORR of 68%, a remarkable CNS response of 91%, and a median PFS of 18.4 months [8].